NASDAQ: TGTX · Biotechnology

TG Therapeutics (TGTX) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values TG Therapeutics (TGTX) at $75.36 a share. The stock last closed at $62.76, which puts the model's fair value 20.1% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 16 Nov 2026. TG Therapeutics, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$75.36midpoint of 2,000 simulations
Last close$62.76NASDAQ: TGTX
Gap to fair value+20.1%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $69.85 to $75.36 (+7.9%). The multiple the model anchors on moved, lifting the fair value: most of the move.

What the model makes of itThe price of $62.76 is 20.1% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 25 Feb 2027. Options prices imply a move of about 15% either way over the next month. On the model's Scorecard Leaders list since 2 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give TGTX?

The calibrated range for TGTX over 63 trading days is $52.91 to $75.09. It sits around the last close, and its width comes from the volatility that TGTX's own options imply (52% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $46.45 to $116.28. In 61% of the simulations the fair value came out above the price the model ran on.

$26.20$223.94
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $75.36. Dashed line: the last close, $62.76.

Faircurve Insights · 14 Nov 2026

TG Therapeutics, Inc. is a biopharmaceutical company based in New York City and established in 1993. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions.

Faircurve's model puts the fair value at $75.36 a share on 14 Nov 2026, the midpoint of 2,000 simulations. This is up from $69.85 on the previous run, on 7 Nov 2026, a move of +7.9%. In the model's own words, the multiple it anchors on moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $54.38 to $77.19, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The business scores 65 out of 100 on the model's composite of six quality factors, measured against comparable companies. Three factors stand out. Growth quality scores 85, with trailing revenue growth of 87.3% against a peer median of 23.8%. Capital discipline scores 88, with net buybacks at 2.1% of market value against a peer median of 0.0%. Profitability scores 81, with ROIC of 15.2% against a peer median of -27.5%. The model compares the company with BioMarin Pharmaceutical Inc. (BMRN), Protagonist Therapeutics, Inc. (PTGX) and Bio-Techne Corporation (TECH).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does TGTX report earnings, and how has the stock reacted?

TG Therapeutics's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 17.2% in either direction through the nearest expiry, about 59 days out. That is the size the market is pricing, not a direction. TGTX's 30 day implied volatility works out to about 14.9% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across TGTX's last 8 reports, ignoring direction, was 6.9%.

0%5%10%15%20%13.1%18.4%3 Mar '2514.6%18.9%4 Aug '2513.9%2.8%3 Nov '2513.4%1.4%26 Feb '269.9%19.2%6 May '2613.9%6.3%3 Aug '2616.5%0.7%2 Nov '2619.6%7.4%9 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in TGTX

10%15%20%25%30%9 Nov '26 report2 Nov '26 report3 Aug '26 report6 May '26 report26 Feb '26 report15% at 11 Nov '2612 Nov '2511 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 17% on 12 Nov 2025, reached 25% on 30 Oct 2026 and reads 15% on 11 Nov 2026. The marks are report dates.

How does TGTX score on business quality?

TG Therapeutics's overall quality score is 65 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.8115.2%ROIC-27.5%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).540.81xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.8587.3%Revenue growth, trailing23.8%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.882.1%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.431.70xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.02557.3 ptsEBITDA margin downside volatility, 5y87.0 pts

How does TGTX compare with similar companies?

The companies in biotechnology closest to TG Therapeutics in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
KRYS Krystal Biotech, Inc.$297.90$352.42+18.3%Low evidence grade
BMRN BioMarin Pharmaceutical Inc.$57.99$69.09+19.1%Undervalued
PTGX Protagonist Therapeutics, Inc.$124.83$104.97-15.9%Overvalued
HALO Halozyme Therapeutics, Inc.$96.50$111.93+16.0%Low evidence grade
TECH Bio-Techne Corporation$72.79$65.76-9.7%Fairly valued
CYTK Cytokinetics, Incorporated$53.17$63.03+18.5%Low evidence grade
ARWR Arrowhead Pharmaceuticals, Inc.$44.21$53.67+21.4%Low evidence grade
LGND Ligand Pharmaceuticals Incorporated$301.71$282.99-6.2%Low evidence grade

What the comparable companies' multiples alone would give for TGTX, the peer-implied price, is $177.88 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

TG Therapeutics at a glance

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions.

Market value
$9.8B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$1.3B
Consensus revenue growth, next fiscal year
+61.2%
Analysts with estimates
3
Beta to the US market
0.52
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. TGTX was among them.

How the fair value is worked out: the model prices TG Therapeutics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for TGTX was $69.85. As of 14 Nov 2026 it is $75.36, a change of +7.9%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about TG Therapeutics's valuation

Is TG Therapeutics stock undervalued or overvalued?

On Faircurve's model, TGTX reads as Undervalued as of 14 Nov 2026. The model's fair value is $75.36 a share against a last close of $62.76, a gap of +20.1%.

What is TGTX's fair value?

$75.36 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $46.45 to $116.28.

What price range does the model give TGTX?

$52.91 to $75.09 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does TG Therapeutics report earnings next?

The next report is scheduled for 25 Feb 2027. Companies can move their dates.

How much has TGTX moved on past earnings reports?

Across its last 8 reports the median two session move was 6.9%, ignoring direction. The largest was +19.2% around the report of 6 May 2026.

How confident is the model in this valuation?

The model's evidence grade for TGTX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on TGTX

The model has an idea open on TGTX under Scorecard Leaders since 2 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on TGTX with their outcomes. A free account is enough.

Keep reading